EMEA-001635-PIP03-17 - paediatric investigation plan

Tanezumab

Key facts

• Active Substance:
  Tanezumab
• Therapeutic area:
  Pain
• Decision number:
  P/0070/2018
• PIP number:
  EMEA-001635-PIP03-17
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  • Treatment of chronic musculoskeletal pain
  • Treatment of chronic pain (excluding musculoskeletal pain)
• Route(s) of administration:
  • Subcutaneous use
  • Intravenous use
• Contact for public enquiries:

  Pfizer Limited

  Tel. + 44 1304646607; E-mail: [e-mail]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  16/03/2018

Decision

P/0070/2018: EMA decision of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for tanezumab (EMEA-001635-PIP03-17)

AdoptedReference Number: EMA/102436/2018